IMMX News and Press, Immix Biopharma Inc. From 10/06/23

2023-10-06 11:25:33 ET Summary Welcome to another installment of our monthly Rare Buy article where we highlight September investment picks you may have missed. As you know some Seeking Alpha analysts are more discerning by nature. Others are finding compelling ideas hard to come ...

2023-10-05 10:00:20 ET More on Health Care Select Sector SPDR BofA Securities: Which small cap non-earner stocks to avoid Citi turns cautious on pharmaceuticals and biotech For further details see: Orchard Therapeutics, Longeveron among healthcare movers

Shares of Immix Biopharma, Inc. (NASDAQ: IMMX) traded at a new 52-week high today and are currently trading at $4.6. So far today, approximately 104.97k shares have been exchanged, as compared to an average 30-day volume of 318.21k shares. Immix Biopharma, Inc., a clinical-stage biopharmaceut...

100% (9/9) overall response rate and 67% (6/9) complete response rate (MRD 10 -5 ) observed in heavily pre-treated patients with daratumumab relapsed/refractory AL Amyloidosis as of the September 20, 2023 data cutoff 100% (4/4) overall response rate and 75% (3/4) complete response rate ob...

2023-10-02 10:00:06 ET More on Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) BofA Securities: Which small cap non-earner stocks to avoid Health Care Select Sector SPDR ETF declares quarterly distribution of $0.53...

95% overall response rate observed in relapsed/refractory multiple myeloma patients not previously treated with BCMA-targeted therapy. Median progression free survival (mPFS) was 12.9 months as of the July 17, 2023 data cut-off 90% overall response rate observed in relapsed/refractory multipl...

2023-09-25 16:29:57 ET More on Immix Biopharma, Inc. Seeking Alpha’s Quant Rating on Immix Biopharma, Inc. Historical earnings data for Immix Biopharma, Inc. Financial information for Immix Biopharma, Inc. Immix Biopharma: A Mid-To-Late Stage CAR-T Bio...

2023-09-21 12:53:20 ET More on Immix Historical earnings data for Immix Biopharma, Inc. Financial information for Immix Biopharma, Inc. Immix Biopharma: A Mid-To-Late Stage CAR-T Biotech Quietly Gaining Momentum Immix gets FDA orphan drug designation for NXC-...

FDA Orphan Drug Designation (“ODD”) qualifies one-time treatment NXC-201 for: 7 years of U.S. market exclusivity after approval Tax credits for qualified clinical testing Waiver of the Prescription Drug User Fee (currently at almost $3 million for a new drug) The A...

2023-09-19 13:49:41 ET More on Immix Biopharma: Seeking Alpha’s Quant Rating on Immix Biopharma, Inc. Historical earnings data for Immix Biopharma, Inc. Financial information for Immix Biopharma, Inc. Immix Biopharma: A Mid-To-Late Stage CAR-T Biotech ...